Tag Archive | "University of Utah"

Gene found that may predict lung cancer in smokers

Tags: , , , , , , ,


Researchers have identified a group of genes that are especially active in lung cancer patients — even in healthy tissue — and said they may be used to predict which smokers will eventually develop lung cancer.

And, they said, a natural supplement derived from food that is being tested to prevent lung cancer appears to halt the precancerous changes.

“Even in normal cells or premalignant cells prior to cancer development we see this pathway being turned on,” said Andrea Bild of the University of Utah, who worked on the study published in the journal Science Translational Medicine.

The main gene is called PI3K and it affects a pathway of other genes, Bild, Avrum Spira of Boston University and colleagues reported. And it can be found in the windpipes of smokers, meaning they do not need more dangerous and uncomfortable lung tests.

“These cells are like a canary in the coal mine,” Spira said in a telephone interview. “Even though lung cancer develops deep down in your lungs when you smoke, these cells can tell you whether you are on the way to developing lung cancer. It is sort of a window into the lung.”

Cigarette smoke causes 90 percent of all cases of lung cancer, which kills 1.2 million people a year globally.

But only about 10 percent of smokers ever develop lung cancer, although they often die of other causes such as heart disease, stroke or emphysema.

Spira and Bild put together results from two ongoing trials of smokers.

“The patients walk in the door and they have something wrong with them — we don’t know what. Maybe they have lung cancer, maybe they have something else,” Bild said in a telephone interview.

Lung cancer is so deadly precisely because it causes vague symptoms. Most patients are not diagnosed until it has spread and can no longer be treated.

ACTIVE GENES

The researchers used a brush to collect cells from the windpipes of the smokers. They put these on a gene chip or microarray to see which genes were active in the cells.

“We found this certain pathway, PI3K, was turned on in patients that had lung cancer as opposed to patients that had other problems,” Bild said.

PI3K had long been suspected in lung cancer. But another experiment got the researchers more excited.

These were patients with precancerous lesions in their lungs called dysplasia. PI3K was also active in their lesions.

And the second group was taking the natural supplement, myo-inositol, to try to prevent lung cancer. In the patients whose lesions shrank after taking the supplement, PI3K also became less active, the researchers found.

“Together it gives us the story of the importance of this pathway,” Bild added. “Whether it is going to save millions of people, who knows?”

Spira said he is working with Boston-based Allegro Diagnostics, which is halfway through a 60-patient clinical trial of the test.

The researchers have patented their findings through the universities but Bild said myo-inositol supplements are cheap and freely available.

Myo-inositol is also found in fruits, beans, grains and nuts, although Bild said the finding does not necessarily explain why people who eat more of these foods have a lower risk of cancer in general.

Source: Reuters

Popularity: 3% [?]

U. Alzheimer’s Center seeks patients for trial of new drug

Tags: , , , , , , , ,


Researchers at the University of Utah are seeking at least 10 patients age 50 and older with mild to moderate Alzheimer’s to participate in a national trial of an experimental medication.

The drug is aimed at nerve damage and inflammation in the brain that can lead to progressive memory loss and behavioral changes in people with Alzheimer’s disease.

[ad]

The Utah portion of the study is led by Edward Y. Zamrini, associate professor of neurology at the U School of Medicine. He is also director of clinical trials at the Center for Alzheimer’s Care, Imaging and Research, one of 40 centers across the nation in the study.

People interested in joining the industry-sponsored trial can contact the study line at (801) 587-7888.

Doctors and nurses will monitor the participants during regular visits and measure the severity and progression of disease using standard tests of functional and cognitive abilities.

Neither the researchers nor the participants will know who is receiving the study drug and who is getting the placebo.

Doctors also will examine biological markers of the disease, through scans and other testing, Zamrini said in a statement.

A protein called amyloid beta builds up in plaque deposits and can trigger inflammation in the brains of people with Alzheimer’s disease. The trial will test an experimental drug that seeks to stop amyloid beta from binding to a receptor in the brain called RAGE (receptor for advanced glycation endproducts).

The drug has been tested in animals and in preliminary human studies. This Phase II clinical trial is intended to determine whether it will slow the progressive decline associated with Alzheimer’s disease.

The 18-month study is being conducted by the Alzheimer’s Disease Cooperative Study, a consortium of leading researchers supported by the National Institute on Aging.

“Progress in treating and preventing Alzheimer’s would just not be possible without the dedication of the patients and families who volunteer for clinical trials,” said Neil Buckholtz, Ph.D., chief of the NIA Dementias of Aging Branch, in a statement.

Resources on the Web

– The Center for Alzheimer’ Care, Imaging and Research invites thosse interested in its memory-related research to register online at www.utahmemory.org. Click on the “Join Our Research” link to the left.

– To view a list of the research sites or for information on dementia and aging, go to http://www.nia.nih.gov/Alzheimers.

Source: The Salt Lake Tribune

Popularity: 3% [?]

Site Sponsors